Jove
Visualize
お問い合わせ

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Isopropyl 3-(3,4-Dihydroxyphenyl)-2-Hydroxypropanoate Attenuates Experimental Renal Ischemia-Reperfusion Injury by Limiting Sterile Inflammation and Preserving Mitochondrial Function: Involvement of an Nrf2-Associated Cytoprotective Response.

Journal of inflammation research·2026
Same author

Synergistic regulation of iron cycle and hydroxyl radical generation in sodium percarbonate-based Fenton reaction enables efficient degradation of chlorinated hydrocarbons.

Journal of hazardous materials·2026
Same author

A Quantum Self-Attention Neural Network Model on Quantum Circuits.

IEEE transactions on cybernetics·2026
Same author

Construction of phosphorus and cobalt co-modified tubular carbon nitride with dual reaction sites for boosted imidacloprid degradation.

Journal of colloid and interface science·2026
Same author

Latent profile analysis of digital health literacy among community-dwelling older adults and its influencing factors.

Digital health·2026
Same author

Four-dimensional left ventricular motion clustering reveals cardiovascular phenotypes at population scale.

Scientific reports·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

Manuela Polydoro1, Ivana Geric2, Jin Zheng1

  • 1Muna Therapeutics, Copenhagen, Capital Region, Denmark.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ

新規TREM2アゴニストであるMTX46943は、TREM2/DAP12複合体を安定化させることによりミクログリアを活性化し、アルツハイマー病の病状を軽減します。この低分子治療薬は、初期ADの治療薬としての可能性を示しています。

キーワード:
TREM2アゴニストMTX46943ミクログリア活性化アルツハイマー病TREM2/DAP12複合体低分子治療薬

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学分野:

  • 神経科学; 免疫学; 薬理学

背景:

  • ミクログリアは脳の主要な自然免疫細胞であり、健康維持とアルツハイマー病（AD）病理の解決に不可欠です。TREM2（Triggering Receptor Expressed on Myeloid cells 2）は、ミスフォールドタンパク質に対するミクログリア応答を調節する受容体であり、神経機能に不可欠です。MTX46943は、初期AD治療を目的としたTREM2を標的とする、新規で強力、選択的、安全かつ脳内移行可能な低分子アゴニストです。

研究 の 目的:

  • TREM2アゴニストであるMTX46943の作用機序と有効性を調査し、ミクログリアの活性化とAD病理の軽減を目的としました。TREM2受容体複合体ダイナミクスとミクログリア機能に対するMTX46943の下流効果を特徴づけることを目的としました。ADのマウスモデルにおけるアミロイド病理に対する慢性MTX46943治療のin vivoでの影響を評価することを目的としました。

主な方法:

  • 様々な細胞種におけるTREM2活性化と下流効果を評価するために、in vitroアッセイ（nanoBiT、ウェスタンブロット、alphaLISA、遊走、食作用）を使用しました。受容体活性化様式を区別するために、TREM2アゴニスト抗体との比較を行いました。in vivo研究では、5xFAD // hTREM2ノックインマウスの慢性治療を行い、qPCR、単一細胞RNAシーケンシング、免疫染色を用いてミクログリアと脳組織を分析しました。

主要な成果:

  • MTX46943は、ミクログリア活性化に不可欠なTREM2/DAP12受容体複合体の形成を促進し、その表面存在を安定化させます。これは抗体アゴニストとは異なる作用機序です。in vivoでは、MTX46943治療により、アミロイド病理が存在する条件下でミクログリアが再プログラムされ、神経毒性アミロイドβ種の著しい減少につながりました。in vivoで観察された効果は、脳内移行可能な曝露レベルでのMTX46943のin vitroでの効力と一致していました。

結論:

  • 選択的TREM2アゴニストであるMTX46943は、初期アルツハイマー病治療のための臨床試験に進んでいます。本研究は、TREM2受容体複合体の安定化とミクログリアの再プログラム化を含む、MTX46943の差別化された作用機序を実証しました。慢性MTX46943治療は、脳のアミロイド病理を著しく減少し、ADのベストインクラス治療薬としての可能性を支持します。